Kaushalkumar Dave1,2, Fahd M Alsharif1,3, Saiful Islam1, Chandradhar Dwivedi1, Omathanu Perumal4. 1. Department of Pharmaceutical sciences, College of Pharmacy, South Dakota State University,, Brookings, South Dakota, USA. 2. Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research,, Food and Drug Administration, Silver Spring, Maryland, USA. 3. College of Pharmacy, Al-Azhar University,, Assiut, Egypt. 4. Department of Pharmaceutical sciences, College of Pharmacy, South Dakota State University,, Brookings, South Dakota, USA. omathanu.perumal@sdstate.edu.
Abstract
PURPOSE: Almost all breast cancers originate from epithelial cells lining the milk ducts in the breast. To this end, the study investigated the feasibility of localized transdermal delivery of α-santalol, a natural chemopreventive agent to the breast. METHODS: Different α-santalol formulations (cream, solution and microemulsion) were developed and the in vitro permeability was studied using excised animal (porcine and rat) and human breast skin/mammary papilla (nipple). The in vivo biodistribution and efficacy studies were conducted in female rats. A chemical carcinogenesis model of breast cancer was used for the efficacy studies. RESULTS: Phospholipid based α-santalol microemulsion showed the highest penetration through the nipple and breast skin. Delivery of α-santalol through the entire breast (breast skin and nipple) in vivo in rats resulted in significantly higher concentration in the mammary gland compared to transdermal delivery through the breast skin or nipple. There was no measurable α-santalol concentration in the blood. Transdermal delivery of α-santalol reduced the tumor incidence and tumor multiplicity. Furthermore, the tumor size was significantly reduced with α-santalol treatment. CONCLUSIONS: The findings from this study demonstrate the feasibility of localized transdermal delivery of α-santalol for chemoprevention of breast cancer.
PURPOSE: Almost all breast cancers originate from epithelial cells lining the milk ducts in the breast. To this end, the study investigated the feasibility of localized transdermal delivery of α-santalol, a natural chemopreventive agent to the breast. METHODS: Different α-santalol formulations (cream, solution and microemulsion) were developed and the in vitro permeability was studied using excised animal (porcine and rat) and human breast skin/mammary papilla (nipple). The in vivo biodistribution and efficacy studies were conducted in female rats. A chemical carcinogenesis model of breast cancer was used for the efficacy studies. RESULTS:Phospholipid based α-santalol microemulsion showed the highest penetration through the nipple and breast skin. Delivery of α-santalol through the entire breast (breast skin and nipple) in vivo in rats resulted in significantly higher concentration in the mammary gland compared to transdermal delivery through the breast skin or nipple. There was no measurable α-santalol concentration in the blood. Transdermal delivery of α-santalol reduced the tumor incidence and tumor multiplicity. Furthermore, the tumor size was significantly reduced with α-santalol treatment. CONCLUSIONS: The findings from this study demonstrate the feasibility of localized transdermal delivery of α-santalol for chemoprevention of breast cancer.
Entities:
Keywords:
breast cancer; chemoprevention; microemulsion; transdermal; α-santalol
Authors: Satoshi Murata; Scott L Kominsky; Mustafa Vali; Zhe Zhang; Elizabeth Garrett-Mayer; Dorian Korz; David Huso; Sharyn D Baker; James Barber; Elizabeth Jaffee; R Todd Reilly; Saraswati Sukumar Journal: Cancer Res Date: 2006-01-15 Impact factor: 12.701
Authors: Fahd M Alsharif; Kaushalkumar Dave; Ahmed M Samy; Khaled I Saleh; Mohamed A Amin; Omathanu Perumal Journal: AAPS PharmSciTech Date: 2016-08-09 Impact factor: 3.246
Authors: Ajay Bommareddy; Karryn Crisamore; Sarah Fillman; Sarah Brozena; James Steigerwalt; Terra Landis; Adam L Vanwert; Chandradhar Dwivedi Journal: Anticancer Res Date: 2015-10 Impact factor: 2.480
Authors: D M Vigushin; G K Poon; A Boddy; J English; G W Halbert; C Pagonis; M Jarman; R C Coombes Journal: Cancer Chemother Pharmacol Date: 1998 Impact factor: 3.333
Authors: Carmen Ortiz; Luisa Morales; Miguel Sastre; William E Haskins; Jaime Matta Journal: Evid Based Complement Alternat Med Date: 2016-05-11 Impact factor: 2.629